Shareholding6 Oct 2026, 10:26 am
Bliss GVS Pharma: Catalyst Trusteeship Pledges 47.95% Shares
AI Summary
Catalyst Trusteeship Limited, acting as Debenture Trustee on behalf of debenture holders, has disclosed the pledge of 5,09,84,595 equity shares of Bliss GVS Pharma Ltd. This represents 47.95% of the total share capital and 46.77% of the total diluted share capital. The pledge was made on September 30, 2026. This disclosure is made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Key Highlights
- Catalyst Trusteeship pledges 5,09,84,595 shares of Bliss GVS Pharma.
- Pledged shares constitute 47.95% of total share capital.
- Disclosure filed under SEBI Takeover Regulations.
- Pledge is on behalf of debenture holders.
- Pledge effective from September 30, 2026.
Price Impact
More from BLISSGVS